טוען...
Tyrosine kinase inhibitors re-treatment beyond progression: choice and challenge
Tyrosine kinase inhibitors (TKIs) are highly effective agents for the treatment of lung cancer which harbors activated gene mutation. However, for patients with failure of TKI, TKI re-treatment beyond progression (TRBP) is still a potential option that has been proven by many literatures. In this re...
שמור ב:
| Main Authors: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Pioneer Bioscience Publishing Company
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4073393/ https://ncbi.nlm.nih.gov/pubmed/24976979 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2072-1439.2014.04.36 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|